NCT06719206 Reduce Sedentary Behavior During Cancer Treatment - the RedSedCan Study
| NCT ID | NCT06719206 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mälardalen University |
| Condition | Breast Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 172 participants |
| Start Date | 2025-03-01 |
| Primary Completion | 2029-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 172 participants in total. It began in 2025-03-01 with a primary completion date of 2029-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Summary Reducing sedentary behavior during treatment is important to reduce the risk of future health problems in individuals undergoing cancer treatment. Therefore, the goal of this project is with a multicenter randomised controlled design investigate whether a digital support intervention during ongoing neo- or adjuvant cancer treatment for breast, prostate or colon cancer is effective in reducing sedentary lifestyle and improving well-being in the short and long term.
Eligibility Criteria
Inclusion Criteria: * Individuals diagnosed with breast, prostate, or colorectal cancer planned for or resently started neo- or adjuvant treatment (e.g. chemotherapy, radiotherapy, endocrine treatment) at the hospitals in Uppsala and Västerås, Sweden. Exclusion Criteria: * Individuals diagnosed with dementia. * Individuals diagnosed with severe psychiatric disease. * Individuals with severe loss of vision, or communicative ability. * Individuals who cannot walk independently indoors with or without a walking aid. * Individuals completed treatment for other cancer diseases less than 12 months ago or not recovered from previous cancer treatment.
Contact & Investigator
Petra von Heideken Wågert, Professor
PRINCIPAL INVESTIGATOR
Mälardalen University
Frequently Asked Questions
Who can join the NCT06719206 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06719206 currently recruiting?
Yes, NCT06719206 is actively recruiting participants. Contact the research team at petra.heideken.wagert@mdu.se for enrollment information.
Where is the NCT06719206 trial being conducted?
This trial is being conducted at Uppsala, Sweden, Västerås, Sweden.
Who is sponsoring the NCT06719206 clinical trial?
NCT06719206 is sponsored by Mälardalen University. The principal investigator is Petra von Heideken Wågert, Professor at Mälardalen University. The trial plans to enroll 172 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.